๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Hepatic Impairment

Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment NCT07036133Phase 14 sites๐Ÿ“ Cerritos๐Ÿ“ Chicago๐Ÿ“ Detroit Acrotech Biopharma Inc. ยท Tests: Pralatrexate Injection Radiprodil in Participants With Hepatic Impairment NCT07457229Phase 12 sites๐Ÿ“ DeSoto๐Ÿ“ San Antonio GRIN Therapeutics, Inc. ยท Tests: Radiprodil Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease NCT05045482Phase 11 site๐Ÿ“ Indianapolis Zydus Therapeutics Inc. ยท Tests: Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment NCT04953910Phase 122 sites๐Ÿ“ Houston๐Ÿ“ Yerevan๐Ÿ“ Yerevan Taiho Oncology, Inc. ยท Tests: ASTX727 A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function NCT07269301Phase 13 sites๐Ÿ“ Lake Forest๐Ÿ“ Orlando๐Ÿ“ Tampa Pfizer ยท Tests: PF-07328948 Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment NCT07282093Phase 11 site๐Ÿ“ Suzhou Ascentage Pharma Group Inc. ยท Tests: Olverembatinib 20mg To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects NCT07480824Phase 12 sites๐Ÿ“ Luoyang๐Ÿ“ Jinan Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ยท Tests: TQ05105 A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment NCT07343960Phase 12 sites๐Ÿ“ Rialto๐Ÿ“ San Antonio AstraZeneca ยท Tests: Capivasertib Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment NCT04617522Phase 115 sites๐Ÿ“ Long Beach๐Ÿ“ Newark๐Ÿ“ Baltimore Gilead Sciences ยท Tests: Sacituzumab Govitecan-hziy A Study of Efimosfermin Alfa in Adults With Hepatic Impairment NCT07358546Phase 13 sites๐Ÿ“ Rialto๐Ÿ“ Tampa๐Ÿ“ San Antonio GlaxoSmithKline ยท Tests: Efimosfermin alfa The Liver Cirrhosis Cognitive Decline Scale (LiCCoS) NCT07418008n/a1 site๐Ÿ“ Ambฤla University of Malaya A Pharmacokinetic Study of D-2570 in Participants With Hepatic Impairment and Normal Hepatic Function NCT07715149Phase 11 site๐Ÿ“ Bengbu InventisBio Co., Ltd ยท Tests: D-2570 Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease NCT06825559Phase 11 site๐Ÿ“ Indianapolis Zydus Therapeutics Inc. ยท Tests: Saroglitazar Magnesium 1 mg A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine NCT06682988Phase 252 sites๐Ÿ“ Sarasota๐Ÿ“ Edgewood๐Ÿ“ Lexington AbbVie ยท Tests: Mirvetuximab Soravtansine Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function NCT07751250Phase 11 site๐Ÿ“ San Antonio Arcus Biosciences, Inc. ยท Tests: Casdatifan A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems NCT07486102Phase 11 site๐Ÿ“ San Antonio Boehringer Ingelheim ยท Tests: BI 3000202 A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment NCT07165002Phase 13 sites๐Ÿ“ Kistarcsa๐Ÿ“ Auckland๐Ÿ“ Bratislava Eli Lilly and Company ยท Tests: LY3537031 A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and Normal Liver Function NCT07694843Phase 11 site๐Ÿ“ Suzhou CSPC ZhongQi Pharmaceutical Technology Co., Ltd. ยท Tests: ammoxetine hydrochloride enteric-coated tablets A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment NCT07643155Phase 14 sites๐Ÿ“ Lake Forest๐Ÿ“ San Dimas๐Ÿ“ Orlando Insmed Incorporated ยท Tests: Treprostinil Palmitil Inhalation Powder A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function NCT07231991Phase 14 sites๐Ÿ“ Miami๐Ÿ“ Miami Lakes๐Ÿ“ Orlando Pfizer ยท Tests: vepdegestrant Pharmacokinetic Study of Vorolanib Tablets in Trial Participants With Hepatic Impairment NCT07809802Phase 11 site๐Ÿ“ Changchun Betta Pharmaceuticals Co., Ltd. ยท Tests: vorolanib, vorolanib, Vorolanib Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib NCT06997276Phase 13 sites๐Ÿ“ Miami๐Ÿ“ Orlando๐Ÿ“ San Antonio SpringWorks Therapeutics, Inc., a healthcare company of Merโ€ฆ ยท Tests: Mirdametinib (MEK Inhibitor) e-ALIGN: A Patient Portal-based Intervention to Align Medications With What Matters Most NCT07454824NA1 site๐Ÿ“ Baltimore Johns Hopkins University ยท Tests: e-ALIGN Patient-Portal Deprescribing A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement NCT06985615Phase 11 site๐Ÿ“ Suzhou Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. ยท Tests: Single dose of HDM1002 on Day 1 A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease NCT07677358Phase 13 sites๐Ÿ“ Miami Lakes๐Ÿ“ Orlando๐Ÿ“ Tampa Pfizer ยท Tests: Atirmociclib Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function NCT07682818Phase 13 sites๐Ÿ“ Wroclaw๐Ÿ“ Bratislava๐Ÿ“ Malacky Zealand Pharma ยท Tests: Petrelintide Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI) NCT06962332Phase 12 sites๐Ÿ“ Orlando๐Ÿ“ San Antonio Exelixis ยท Tests: Zanzalintinib A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of HS-10506 NCT07844967Phase 11 site๐Ÿ“ Hefei Jiangsu Hansoh Pharmaceutical Co., Ltd. ยท Tests: HS-10506 Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants NCT07250633Phase 13 sites๐Ÿ“ Chandler๐Ÿ“ Orlando๐Ÿ“ San Antonio Institut de Recherches Internationales Servier (I.R.I.S.) ยท Tests: Vorasidenib 20mg Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment NCT07152288Phase 11 site๐Ÿ“ Beijing Haisco Pharmaceutical Group Co., Ltd. ยท Tests: HSK39297 tablets, HSK39297 tablets, HSK39297 tablets
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy